Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review

Lung adenocarcinoma is the most common pathologic pattern of lung cancer. During the past decades, a number of targeted agents have been explored to treat advanced lung adenocarcinoma. Recently, Crizotinib, the antagonist of anaplastic lymphoma kinase (ALK), has been widely used in ALK-rearranged lu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicine (Baltimore) 2018-11, Vol.97 (48), p.e13088-e13088
Hauptverfasser: Zheng, Shu-Yue, Shen, Wen, Peng, Yan-Mei, Cui, Hui-Juan, Duan, Hua, Qiu, Yu-Qin, Li, Qiang, Zhang, Jing-Yi, Sun, Chen-Yao, Zhang, Xu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e13088
container_issue 48
container_start_page e13088
container_title Medicine (Baltimore)
container_volume 97
creator Zheng, Shu-Yue
Shen, Wen
Peng, Yan-Mei
Cui, Hui-Juan
Duan, Hua
Qiu, Yu-Qin
Li, Qiang
Zhang, Jing-Yi
Sun, Chen-Yao
Zhang, Xu
description Lung adenocarcinoma is the most common pathologic pattern of lung cancer. During the past decades, a number of targeted agents have been explored to treat advanced lung adenocarcinoma. Recently, Crizotinib, the antagonist of anaplastic lymphoma kinase (ALK), has been widely used in ALK-rearranged lung cancer treatment. Crizotinib is generally well tolerated while its most frequent adverse events include visual disorders, gastrointestinal disturbances, cardiac and endocrine abnormalities. Rash caused by crizotinib is rarely seen, and there are few case reports of severe rash caused by crizotinib. Here we report cases of an 81-year-old man and a 66-year-old woman with ALK-rearranged advanced lung adenocarcinoma. When patients came to our department, they both had crizotinib-induced severe rash. Crizotinib was initiated as the 1st-line treatment without other therapies. We treated severe rash with traditional Chinese medicine (TCM) therapy called Zhiyang Pingfu liquid along with Western medicine. Zhiyang Pingfu liquid consists of Scutellaria baicalensis 20 g, Portulaca oleracea 30 g, Cortex Dictamni 30 g, Sophora flavescens 30 g, and other substances. Western medicine includes Minocycline hydrochloride tablets and Aprepitant capsules. Both patients achieved a partial response when treated with crizotinib, and suffered from severe rash. With Zhiyang Pingfu liquid and Western medicine, their rash gradually disappeared with no sign of cancer progression. Also the male patient did not relieve after taking only antibiotics (standard therapy) and anti-allergic medicine. Despite the dramatic benefit of crizotinib for patients with ALK rearrangement, crizotinib-induced severe rash needs to be dealt with caution. This is the 1st case in which TCM and Western medicine are used to successfully treat crizotinib-induced severe rash. The mechanism of crizotinib-induced rash deserves further attention in future research.
doi_str_mv 10.1097/MD.0000000000013088
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6283193</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>30508887</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2857-dc4b2121141a84d5f798f4e201b7c8eb9e7311ff2c376b824d7f0b6912309f913</originalsourceid><addsrcrecordid>eNpdkd9uFCEUxonR2LX6BCaGF5iWfzOAFyZmW6tJm96s8ZIwzBkHnR02wO6kvoVvLNu1Wy0XcHL4fd-BcxB6S8kZJVqe31yckcdFOVHqGVrQmjdVrRvxHC0IYXUltRQn6FVKP_aQZOIlOuGkLrSSC_R7FcHmNUwZhx4n2EEEHG0asLPbBB1u77CL_lfIfvItnn0ecBvKlqPtfPZhsiNeDn6CBHgNnXclxHbq8DdIGeJ0TL7HqzkU18JF2ISY0z02-kLZvN2XhZ2H-TV60dsxwZu_5yn6-ulytfxcXd9efVl-vK4cU7WsOidaRhmlglolurqXWvUCGKGtdApaDZJT2vfMcdm0iolO9qRtNGWc6F5Tfoo-HHw327a80ZUWRDuaTfRrG-9MsN78fzP5wXwPO9MwxanmxYAfDFwMKUXoj1pKzH5C5ubCPJ1QUb37t-xR8zCSAogDMIextCb9HLczRDOAHfNw71dLzaryUUWLJan2Kcn_AOHon14</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wolters Kluwer Open Health</source><source>IngentaConnect Free/Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Zheng, Shu-Yue ; Shen, Wen ; Peng, Yan-Mei ; Cui, Hui-Juan ; Duan, Hua ; Qiu, Yu-Qin ; Li, Qiang ; Zhang, Jing-Yi ; Sun, Chen-Yao ; Zhang, Xu</creator><creatorcontrib>Zheng, Shu-Yue ; Shen, Wen ; Peng, Yan-Mei ; Cui, Hui-Juan ; Duan, Hua ; Qiu, Yu-Qin ; Li, Qiang ; Zhang, Jing-Yi ; Sun, Chen-Yao ; Zhang, Xu</creatorcontrib><description>Lung adenocarcinoma is the most common pathologic pattern of lung cancer. During the past decades, a number of targeted agents have been explored to treat advanced lung adenocarcinoma. Recently, Crizotinib, the antagonist of anaplastic lymphoma kinase (ALK), has been widely used in ALK-rearranged lung cancer treatment. Crizotinib is generally well tolerated while its most frequent adverse events include visual disorders, gastrointestinal disturbances, cardiac and endocrine abnormalities. Rash caused by crizotinib is rarely seen, and there are few case reports of severe rash caused by crizotinib. Here we report cases of an 81-year-old man and a 66-year-old woman with ALK-rearranged advanced lung adenocarcinoma. When patients came to our department, they both had crizotinib-induced severe rash. Crizotinib was initiated as the 1st-line treatment without other therapies. We treated severe rash with traditional Chinese medicine (TCM) therapy called Zhiyang Pingfu liquid along with Western medicine. Zhiyang Pingfu liquid consists of Scutellaria baicalensis 20 g, Portulaca oleracea 30 g, Cortex Dictamni 30 g, Sophora flavescens 30 g, and other substances. Western medicine includes Minocycline hydrochloride tablets and Aprepitant capsules. Both patients achieved a partial response when treated with crizotinib, and suffered from severe rash. With Zhiyang Pingfu liquid and Western medicine, their rash gradually disappeared with no sign of cancer progression. Also the male patient did not relieve after taking only antibiotics (standard therapy) and anti-allergic medicine. Despite the dramatic benefit of crizotinib for patients with ALK rearrangement, crizotinib-induced severe rash needs to be dealt with caution. This is the 1st case in which TCM and Western medicine are used to successfully treat crizotinib-induced severe rash. The mechanism of crizotinib-induced rash deserves further attention in future research.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000013088</identifier><identifier>PMID: 30508887</identifier><language>eng</language><publisher>United States: the Author(s). Published by Wolters Kluwer Health, Inc</publisher><subject>Adenocarcinoma of Lung - drug therapy ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents - therapeutic use ; Aprepitant - therapeutic use ; Clinical Case Report ; Crizotinib - adverse effects ; Crizotinib - therapeutic use ; Drug Therapy, Combination ; Exanthema - chemically induced ; Exanthema - drug therapy ; Female ; Humans ; Lung Neoplasms - drug therapy ; Male ; Medicine, Chinese Traditional - methods ; Minocycline - therapeutic use</subject><ispartof>Medicine (Baltimore), 2018-11, Vol.97 (48), p.e13088-e13088</ispartof><rights>the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2857-dc4b2121141a84d5f798f4e201b7c8eb9e7311ff2c376b824d7f0b6912309f913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283193/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283193/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30508887$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zheng, Shu-Yue</creatorcontrib><creatorcontrib>Shen, Wen</creatorcontrib><creatorcontrib>Peng, Yan-Mei</creatorcontrib><creatorcontrib>Cui, Hui-Juan</creatorcontrib><creatorcontrib>Duan, Hua</creatorcontrib><creatorcontrib>Qiu, Yu-Qin</creatorcontrib><creatorcontrib>Li, Qiang</creatorcontrib><creatorcontrib>Zhang, Jing-Yi</creatorcontrib><creatorcontrib>Sun, Chen-Yao</creatorcontrib><creatorcontrib>Zhang, Xu</creatorcontrib><title>Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Lung adenocarcinoma is the most common pathologic pattern of lung cancer. During the past decades, a number of targeted agents have been explored to treat advanced lung adenocarcinoma. Recently, Crizotinib, the antagonist of anaplastic lymphoma kinase (ALK), has been widely used in ALK-rearranged lung cancer treatment. Crizotinib is generally well tolerated while its most frequent adverse events include visual disorders, gastrointestinal disturbances, cardiac and endocrine abnormalities. Rash caused by crizotinib is rarely seen, and there are few case reports of severe rash caused by crizotinib. Here we report cases of an 81-year-old man and a 66-year-old woman with ALK-rearranged advanced lung adenocarcinoma. When patients came to our department, they both had crizotinib-induced severe rash. Crizotinib was initiated as the 1st-line treatment without other therapies. We treated severe rash with traditional Chinese medicine (TCM) therapy called Zhiyang Pingfu liquid along with Western medicine. Zhiyang Pingfu liquid consists of Scutellaria baicalensis 20 g, Portulaca oleracea 30 g, Cortex Dictamni 30 g, Sophora flavescens 30 g, and other substances. Western medicine includes Minocycline hydrochloride tablets and Aprepitant capsules. Both patients achieved a partial response when treated with crizotinib, and suffered from severe rash. With Zhiyang Pingfu liquid and Western medicine, their rash gradually disappeared with no sign of cancer progression. Also the male patient did not relieve after taking only antibiotics (standard therapy) and anti-allergic medicine. Despite the dramatic benefit of crizotinib for patients with ALK rearrangement, crizotinib-induced severe rash needs to be dealt with caution. This is the 1st case in which TCM and Western medicine are used to successfully treat crizotinib-induced severe rash. The mechanism of crizotinib-induced rash deserves further attention in future research.</description><subject>Adenocarcinoma of Lung - drug therapy</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Aprepitant - therapeutic use</subject><subject>Clinical Case Report</subject><subject>Crizotinib - adverse effects</subject><subject>Crizotinib - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>Exanthema - chemically induced</subject><subject>Exanthema - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Male</subject><subject>Medicine, Chinese Traditional - methods</subject><subject>Minocycline - therapeutic use</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkd9uFCEUxonR2LX6BCaGF5iWfzOAFyZmW6tJm96s8ZIwzBkHnR02wO6kvoVvLNu1Wy0XcHL4fd-BcxB6S8kZJVqe31yckcdFOVHqGVrQmjdVrRvxHC0IYXUltRQn6FVKP_aQZOIlOuGkLrSSC_R7FcHmNUwZhx4n2EEEHG0asLPbBB1u77CL_lfIfvItnn0ecBvKlqPtfPZhsiNeDn6CBHgNnXclxHbq8DdIGeJ0TL7HqzkU18JF2ISY0z02-kLZvN2XhZ2H-TV60dsxwZu_5yn6-ulytfxcXd9efVl-vK4cU7WsOidaRhmlglolurqXWvUCGKGtdApaDZJT2vfMcdm0iolO9qRtNGWc6F5Tfoo-HHw327a80ZUWRDuaTfRrG-9MsN78fzP5wXwPO9MwxanmxYAfDFwMKUXoj1pKzH5C5ubCPJ1QUb37t-xR8zCSAogDMIextCb9HLczRDOAHfNw71dLzaryUUWLJan2Kcn_AOHon14</recordid><startdate>20181101</startdate><enddate>20181101</enddate><creator>Zheng, Shu-Yue</creator><creator>Shen, Wen</creator><creator>Peng, Yan-Mei</creator><creator>Cui, Hui-Juan</creator><creator>Duan, Hua</creator><creator>Qiu, Yu-Qin</creator><creator>Li, Qiang</creator><creator>Zhang, Jing-Yi</creator><creator>Sun, Chen-Yao</creator><creator>Zhang, Xu</creator><general>the Author(s). Published by Wolters Kluwer Health, Inc</general><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20181101</creationdate><title>Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review</title><author>Zheng, Shu-Yue ; Shen, Wen ; Peng, Yan-Mei ; Cui, Hui-Juan ; Duan, Hua ; Qiu, Yu-Qin ; Li, Qiang ; Zhang, Jing-Yi ; Sun, Chen-Yao ; Zhang, Xu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2857-dc4b2121141a84d5f798f4e201b7c8eb9e7311ff2c376b824d7f0b6912309f913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adenocarcinoma of Lung - drug therapy</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Aprepitant - therapeutic use</topic><topic>Clinical Case Report</topic><topic>Crizotinib - adverse effects</topic><topic>Crizotinib - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>Exanthema - chemically induced</topic><topic>Exanthema - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Male</topic><topic>Medicine, Chinese Traditional - methods</topic><topic>Minocycline - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zheng, Shu-Yue</creatorcontrib><creatorcontrib>Shen, Wen</creatorcontrib><creatorcontrib>Peng, Yan-Mei</creatorcontrib><creatorcontrib>Cui, Hui-Juan</creatorcontrib><creatorcontrib>Duan, Hua</creatorcontrib><creatorcontrib>Qiu, Yu-Qin</creatorcontrib><creatorcontrib>Li, Qiang</creatorcontrib><creatorcontrib>Zhang, Jing-Yi</creatorcontrib><creatorcontrib>Sun, Chen-Yao</creatorcontrib><creatorcontrib>Zhang, Xu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zheng, Shu-Yue</au><au>Shen, Wen</au><au>Peng, Yan-Mei</au><au>Cui, Hui-Juan</au><au>Duan, Hua</au><au>Qiu, Yu-Qin</au><au>Li, Qiang</au><au>Zhang, Jing-Yi</au><au>Sun, Chen-Yao</au><au>Zhang, Xu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2018-11-01</date><risdate>2018</risdate><volume>97</volume><issue>48</issue><spage>e13088</spage><epage>e13088</epage><pages>e13088-e13088</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Lung adenocarcinoma is the most common pathologic pattern of lung cancer. During the past decades, a number of targeted agents have been explored to treat advanced lung adenocarcinoma. Recently, Crizotinib, the antagonist of anaplastic lymphoma kinase (ALK), has been widely used in ALK-rearranged lung cancer treatment. Crizotinib is generally well tolerated while its most frequent adverse events include visual disorders, gastrointestinal disturbances, cardiac and endocrine abnormalities. Rash caused by crizotinib is rarely seen, and there are few case reports of severe rash caused by crizotinib. Here we report cases of an 81-year-old man and a 66-year-old woman with ALK-rearranged advanced lung adenocarcinoma. When patients came to our department, they both had crizotinib-induced severe rash. Crizotinib was initiated as the 1st-line treatment without other therapies. We treated severe rash with traditional Chinese medicine (TCM) therapy called Zhiyang Pingfu liquid along with Western medicine. Zhiyang Pingfu liquid consists of Scutellaria baicalensis 20 g, Portulaca oleracea 30 g, Cortex Dictamni 30 g, Sophora flavescens 30 g, and other substances. Western medicine includes Minocycline hydrochloride tablets and Aprepitant capsules. Both patients achieved a partial response when treated with crizotinib, and suffered from severe rash. With Zhiyang Pingfu liquid and Western medicine, their rash gradually disappeared with no sign of cancer progression. Also the male patient did not relieve after taking only antibiotics (standard therapy) and anti-allergic medicine. Despite the dramatic benefit of crizotinib for patients with ALK rearrangement, crizotinib-induced severe rash needs to be dealt with caution. This is the 1st case in which TCM and Western medicine are used to successfully treat crizotinib-induced severe rash. The mechanism of crizotinib-induced rash deserves further attention in future research.</abstract><cop>United States</cop><pub>the Author(s). Published by Wolters Kluwer Health, Inc</pub><pmid>30508887</pmid><doi>10.1097/MD.0000000000013088</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0025-7974
ispartof Medicine (Baltimore), 2018-11, Vol.97 (48), p.e13088-e13088
issn 0025-7974
1536-5964
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6283193
source MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wolters Kluwer Open Health; IngentaConnect Free/Open Access Journals; PubMed Central; Alma/SFX Local Collection
subjects Adenocarcinoma of Lung - drug therapy
Aged
Aged, 80 and over
Anti-Bacterial Agents - therapeutic use
Aprepitant - therapeutic use
Clinical Case Report
Crizotinib - adverse effects
Crizotinib - therapeutic use
Drug Therapy, Combination
Exanthema - chemically induced
Exanthema - drug therapy
Female
Humans
Lung Neoplasms - drug therapy
Male
Medicine, Chinese Traditional - methods
Minocycline - therapeutic use
title Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T06%3A17%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20severe%20rash%20caused%20by%20crizotinib%20with%20both%20traditional%20Chinese%20medicine%20and%20Western%20medicine:%20Two%20case%20reports%20and%20literature%20review&rft.jtitle=Medicine%20(Baltimore)&rft.au=Zheng,%20Shu-Yue&rft.date=2018-11-01&rft.volume=97&rft.issue=48&rft.spage=e13088&rft.epage=e13088&rft.pages=e13088-e13088&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000013088&rft_dat=%3Cpubmed_cross%3E30508887%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/30508887&rfr_iscdi=true